Case Study
Antibody Drug Design Service

Inquiry
Antibody Drug Design Service
Computational antibody engineering and drug design service

Antibody Drug Design Service for Discovery, Engineering, Optimization & Candidate Prioritization

CD ComputaBio supports antibody drug discovery programs with structure-guided modeling, antibody-antigen interface analysis, affinity optimization, humanization support, developability assessment, and computational candidate prioritization. Our workflow helps research teams connect target biology, antibody sequence, structural models, binding hypotheses, and downstream experimental decisions.

Request an Antibody Design Plan Explore Design Modules See Deliverables
Antibody modeling Antigen interface analysis Affinity optimization Developability review
🧬
From computational design to wet-lab validation
Connect antibody modeling, interface analysis, and candidate prioritization with expression, binding assays, functional testing, and developability evaluation.
🎯
Target-aware antibody optimization
Prioritize antibody designs using epitope location, paratope contacts, CDR contribution, binding risk, specificity, and developability constraints.

What This Service Helps You Decide

Candidate triage

Which antibody candidates should move forward?

Compare candidate sequences and models by target relevance, predicted binding interface, developability risk, and engineering feasibility.

Interface design

Which residues are most important for binding?

Map CDR contribution, paratope-epitope contacts, hydrogen bonds, salt bridges, hydrophobic patches, and mutation-sensitive interface regions.

Engineering direction

How should the antibody be optimized?

Prioritize modifications for affinity, specificity, stability, humanization, aggregation reduction, immunogenicity risk control, or format conversion.

Ask for Project Guidance

Antibody Drug Design Service Coverage

Monoclonal antibody

Monoclonal Antibody Design Services

For programs that need structure-based support for therapeutic mAb discovery, candidate comparison, epitope evaluation, and lead optimization.

  • Heavy/light chain sequence analysis
  • CDR and framework annotation
  • Antibody structure modeling
  • Antigen-binding interface review
  • mAb candidate prioritization
Single domain antibody

Single Domain Antibody Design Service

For VHH, nanobody, and single-domain antibody projects requiring compact-format modeling, paratope analysis, and sequence optimization.

  • VHH/nanobody structure modeling
  • CDR3 and paratope interpretation
  • Target interface prediction
  • Stability and solubility risk review
  • Variant ranking for screening
Polyclonal antibody

Polyclonal Antibody Design Services

For immunogen, antigen region, and epitope selection projects where computational analysis can support broader antibody response design.

  • Antigen region analysis
  • Epitope exposure and conservation review
  • Immunogen design support
  • Peptide antigen prioritization
  • Cross-reactivity risk interpretation
Bispecific antibody

Bispecific Antibody Drugs Design Service

For dual-target antibody programs exploring binding-arm compatibility, spatial feasibility, format selection, and developability risks.

  • Target-pair and epitope compatibility
  • Binding arm arrangement review
  • Format and linker feasibility
  • Dual-interface modeling strategy
  • Developability risk flags
Antigen-antibody design

Hantavirus Antigen & Antibody Modeling and De Novo Design Service

For antigen-antibody modeling and de novo antibody design projects that require target-aware structure modeling and interface-driven candidate generation.

  • Antigen structure and epitope analysis
  • Antibody-antigen complex modeling
  • Target-aware CDR design
  • Candidate diversity and plausibility filtering
  • Design shortlist and validation plan
Optimization

Antibody Optimization and Developability Support

For improving antibody candidates after format selection through affinity, stability, liability, and manufacturability-oriented computational review.

  • Affinity maturation support
  • Humanization risk review
  • Aggregation-prone patch evaluation
  • Sequence liability detection
  • Mutation matrix prioritization

Comparison of Antibody Drug Design Modules

Application Scenario / Project Need Recommended Design Module Best Input Data Typical Output Useful Next Step
  • Antibody sequence is available
  • No reliable structure has been prepared
  • Need a model for downstream design
 Antibody Structure Modeling Heavy/light chain sequences, species, format, numbering scheme 3D antibody model, CDR annotation, model-quality notes, structural risk flags Interface docking or developability assessment
  • Antigen structure is available
  • Need to understand binding mode
  • Need epitope or paratope hypothesis
 Antibody-Antigen Docking Antibody model, antigen structure, known epitope, mutagenesis or binding data Complex poses, contact map, epitope/paratope interpretation, mutation candidates Wet-lab binding validation or MD simulation
  • Lead antibody needs better affinity
  • CDR mutations are being considered
  • Need a rational mutation matrix
 Affinity Optimization Sequence, structure model, binding data, target constraints, known liabilities Prioritized mutation list, residue-level rationale, binding-risk interpretation Focused library design and experimental screening
  • Candidate is non-human or partially humanized
  • Need lower immunogenicity risk
  • Need to preserve binding
 Humanization Support Parental antibody sequence, species source, binding region, desired format Humanized sequence options, framework risk review, back-mutation suggestions Expression and binding comparison
  • Candidate has aggregation or stability concerns
  • Need manufacturability triage
  • Need to reduce sequence liabilities
 Developability Assessment Sequence, structure model, expression data if available, formulation context Liability map, aggregation risk, surface patch interpretation, engineering suggestions Lead selection or sequence refinement
  • Need dual-target or ADC format support
  • Need architecture feasibility review
  • Need design options before construction
 Format-Specific Antibody Design Target pair, antibody arms, epitope information, payload/linker or format constraints Design options, spatial feasibility notes, format risk flags, candidate prioritization Construct design and functional testing

Choose a module based on: antibody format, target structure, binding data, engineering objective, developability risk, validation plan, budget and timeline.

Choose the Right Antibody Design Workflow

Integrated Antibody Drug Design Workflow

Project intake and design objective definition

Clarify whether the project focuses on antibody discovery, lead optimization, target engagement, affinity maturation, humanization, developability, ADC design, or bispecific format planning.

Sequence, structure, and antigen data preparation

Standardize antibody sequences, numbering, antigen structures, epitope information, binding data, and assay context for modeling and comparison.

Antibody modeling and structural quality review

Build or refine antibody structures, evaluate CDR regions, annotate framework features, and identify structural uncertainties that may affect downstream conclusions.

Antibody-antigen interface and binding hypothesis analysis

Predict or evaluate complex structures, map epitope/paratope contacts, identify key interface residues, and compare candidate binding hypotheses.

Engineering, optimization, and developability filtering

Prioritize sequence modifications for affinity, specificity, stability, humanization, aggregation reduction, immunogenicity risk control, or format compatibility.

Reporting and next-step experimental recommendation

Deliver annotated models, ranking tables, mutation rationale, figures, risk interpretation, and recommended validation strategy for the next experimental round.

Start a Project Review

Input Data You Can Provide

  • Antibody heavy and light chain sequences, VHH sequence, Fab/scFv sequence, or candidate FASTA files
  • Antigen structure, AlphaFold model, epitope information, peptide antigen, or target domain definition
  • Binding data such as ELISA, SPR, BLI, neutralization assay, or screening enrichment results
  • Known antibody format, species source, germline information, framework requirements, or Fc format
  • Mutation list, CDR library plan, humanization requirement, developability concern, or ADC conjugation need
  • Project objective such as affinity improvement, specificity design, stability enhancement, or candidate triage

What You Will Receive

  • Prepared antibody and antigen data package with clear modeling assumptions
  • Antibody structure models or antibody-antigen complex models when applicable
  • CDR, paratope, epitope, interface contact, and key-residue interpretation
  • Candidate ranking table with scientific rationale and risk flags
  • Mutation or design suggestions for affinity, specificity, stability, or humanization goals
  • Developability assessment covering aggregation-prone patches, sequence liabilities, and surface properties
  • Final report with figures, model files, method notes, and recommended next-step validation plan
Check My Antibody Input Data

Representative Project Scenarios

Scenario 1

Therapeutic Antibody Candidate Triage

Client need: compare multiple antibody candidates before deeper binding and functional assays.

  • Sequence annotation and structure modeling
  • CDR and framework risk review
  • Target interface hypothesis analysis
  • Candidate ranking and next-step testing plan
Scenario 2

Affinity and Specificity Optimization

Client need: improve antibody binding while minimizing off-target or developability risk.

  • Antibody-antigen complex evaluation
  • CDR hotspot and mutation matrix design
  • Structural and developability filtering
  • Prioritized variants for experimental screening
Scenario 3

ADC or Bispecific Antibody Feasibility

Client need: evaluate whether antibody format, target engagement, or conjugation strategy is suitable.

  • Binding arm and epitope compatibility review
  • Spatial feasibility and linker orientation analysis
  • Sequence liability and conjugation risk review
  • Format-specific design recommendations
Request a Case-Matched Plan

Experimental Validation Support for Antibody Drug Design

Computational antibody design helps prioritize candidates, mutation sites, binding hypotheses, and developability risks. To move from model-based recommendations to experimental decisions, CD ComputaBio can support wet-lab validation planning and coordinated experimental services for antibody binding, function, expression, stability, and candidate comparison.

From design to evidence

Validate antibody candidates before deeper development

Antibody models, docking results, mutation suggestions, and developability predictions are most valuable when they are connected with measurable experimental readouts.

  • Confirm whether designed antibodies bind the intended antigen
  • Compare affinity and specificity across candidate variants
  • Evaluate expression, stability, aggregation, and format feasibility
  • Use experimental data to guide the next optimization round

Antibody Expression and Purification

Support includes: recombinant antibody expression, small-scale production, purification feasibility review, format comparison, and material preparation for downstream binding or functional assays.

Binding Affinity Measurement

Support includes: ELISA, SPR, BLI, antigen-binding comparison, concentration-response analysis, apparent affinity ranking, and confirmation of designed antibody-antigen interactions.

Cell-Based Functional Assays

Support includes: neutralization assays, receptor blocking, signaling inhibition, reporter assays, target engagement, cell viability, internalization, or disease-relevant functional readouts.

Candidate Ranking and Dose-Response Testing

Support includes: side-by-side comparison of designed variants, EC50/IC50 estimation when applicable, replicate testing, control selection, and data-supported candidate prioritization.

Stability and Developability Testing

Support includes: thermal stability, aggregation tendency, purity assessment, stress-condition comparison, sequence-liability follow-up, and manufacturability-oriented candidate review.

Specificity and Counter-Screening

Support includes: cross-reactivity evaluation, related-target comparison, off-target binding review, species cross-reactivity testing, and orthogonal assay planning.

Integrated antibody discovery support: computational design results can be connected with antibody expression, binding validation, functional assays, stability testing, and candidate ranking. This helps clients move from antibody design ideas to experimentally supported development decisions.
Discuss Experimental Validation

Related Service Modules

Monoclonal Antibody DesignSupport monoclonal antibody candidate modeling, screening interpretation, and lead optimization planning.
Single Domain Antibody DesignEvaluate VHH/nanobody structures, paratopes, target interfaces, and sequence optimization options.
Polyclonal Antibody DesignSupport antigen, epitope, and immunogen design strategies for polyclonal antibody programs.
Antibody Affinity PredictionPrioritize candidate antibodies and variants using interface-level binding evidence and structural context.
Antibody Molecular Dynamics SimulationAssess antibody-antigen interface stability, flexibility, mutation effects, and conformational behavior.
ADC Antibody DesignConnect antibody target recognition with ADC suitability, conjugation strategy, and developability considerations.

FAQ

Can the project start with only antibody sequences?

Yes. Antibody sequences can be used for numbering, germline annotation, CDR identification, structure modeling, developability review, and early candidate comparison. Antigen information improves the ability to make target-specific design recommendations.

Can you help design mutations for affinity maturation?

Yes. We can analyze the antibody-antigen interface, identify candidate CDR or framework-adjacent residues, evaluate mutation risks, and prioritize a focused variant set for experimental testing.

Do you support antibody humanization?

Yes. Computational support can include framework comparison, human germline selection, CDR preservation, back-mutation assessment, and structure-based review of binding and stability risks.

Can the workflow support bispecific or ADC projects?

Yes. For bispecific antibodies, we can assess target-pair feasibility, geometry, and format-related risks. For ADC programs, we can support antibody suitability review, target engagement analysis, conjugation site considerations, and linker/payload design context.

What information should I send for a quote?

Please send antibody sequences, antigen information, available structures or models, binding data if available, desired antibody format, optimization objective, and any known developability or experimental constraints.

Ask an Antibody Design Expert

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.

x
Need help getting the data you need?

Talk to our technical team about your project!

I Want To Talk
logo
Give us a free call

Send us an email

Menu Links
Home Services Solutions About Us Contact Us Careers Distributors
Our Services
Protein Structure Modeling Service Protein Sequence Analysis Service Drug Design Services Quantum Chemistry Service
Our Services
In Silico Protein-Protein Interactions Prediction Service Molecular Docking Service Bioinformatics Services Disease Research Services
Our Solutions
Antibody Drug Discovery Service Drug Design Service
Copyright © CD ComputaBio. All Rights Reserved.
Top